台股 » 個股 » 智擎 » 籌碼相關 » 券商分點績效 » 券商分點個股進出

智擎

(4162)
可現股當沖
  • 股價
    96.1
  • 漲跌
    ▲0.9
  • 漲幅
    +0.95%
  • 成交量
    522
  • 產業
    上櫃 生技醫療類股▲0.61%
  • 306人加入追蹤

    立即追蹤

  • 本地時間:14:30

     
智擎 (4162)籌碼相關-元富-西松 券商分點個股進出
券商分點績效/獲利分析

透過統計各券商分點在長期買賣某個股的操作績效,來找出真正獲利的贏家所在券商分點,進而追蹤此贏家所操作的股票與軌跡。

元富-西松 券商分點個股進出

日期買進張數買進均價賣出張數賣出均價收盤價買賣超60日均量成交佔比 大量交易提示
2025/01/221095.201095.8896.1001,1930.00%
2025/01/1300.00497.3096.30-41,370-0.29%
2025/01/10596.04595.7897.0001,3550.00%
2025/01/091198.294295.9294.60-311,341-2.31%
2025/01/087102.2915101.83103.00-81,299-0.62%
2025/01/074102.005101.50101.50-11,275-0.08%
2025/01/0617100.2500.00101.50171,2591.35%
2025/01/0300.00197.6098.30-11,240-0.08%
2025/01/022794.9500.0093.60271,2352.18%
2024/12/2300.00186.9087.00-11,210-0.08%
2024/12/0600.000.693.5093.30-0.61,180-0.05%
2024/12/0500.009395.1694.60-931,170-7.95%
2024/12/0400.00995.4094.60-91,164-0.77%
2024/12/0300.001295.0594.40-121,161-1.03%
2024/12/0200.00698.0594.40-61,158-0.52%
2024/11/2900.0016696.6197.50-1661,136-14.60% 大賣/鉅額交易
2024/11/2800.002792.1892.40-271,110-2.43%
2024/11/26194.103194.2794.00-301,084-2.77%
2024/11/253193.8000.0093.80311,0792.87%
2024/11/20296.851196.2696.50-91,018-0.88%
2024/11/1900.001096.6596.00-101,015-0.98%
2024/11/1800.0025100.7096.50-251,010-2.47%
2024/11/1500.0061101.4399.90-61989-6.16%
2024/11/141107.001101.50101.5009710.00%
2024/11/131106.0000.00106.5019460.11%
2024/11/0700.000.2104.00103.50-0.2852-0.02%
2024/11/051.2107.002106.00106.00-0.8782-0.10%
2024/11/041102.500.2100.50100.000.87580.11%
2024/11/011.2106.639105.11105.00-7.8730-1.07%
2024/10/3000.001101.00102.00-1617-0.16%
2024/10/282101.252102.75102.0005760.00%
2024/10/25899.8000.0097.4085131.56%
2024/10/24297.8012100.4398.30-10494-2.02%
2024/10/23193.10594.1693.70-4424-0.94%
2024/10/151090.0000.0090.20104832.07%
2024/10/09491.2000.0089.5045080.79%
2024/10/087991.81491.1091.107550714.77%
2024/10/073589.1500.0088.80355066.91%
2024/09/306589.8900.0089.506555011.80%
2024/09/271187.7900.0087.80115561.98%
2024/09/2500.00189.5088.20-1609-0.16%
2024/09/247888.6400.0090.207861212.73%
2024/09/233888.0700.0088.00386206.12%
2024/09/204787.9600.0087.40476447.29%
2024/09/194484.8600.0086.00446366.91%
2024/09/181582.9400.0082.90156332.37%
2024/09/09182.0000.0082.0016660.15%
2024/08/22186.6000.0086.6017400.14%
2024/08/2100.00186.7086.60-1746-0.13%
2024/08/140.183.8000.0083.600.17550.01%
2024/08/13084.8000.0084.4007720.00%
2024/08/07087.3000.0086.7007940.00%
2024/08/0500.000.585.0083.00-0.5764-0.07%
2024/07/26196.902197.1397.60-20729-2.74%
2024/07/2200.000.292.6092.00-0.2718-0.03%
2024/07/185100.0013.398.8699.40-8.3676-1.23%
2024/07/1700.001398.3798.20-13658-1.97%
2024/07/16398.901498.8497.00-11658-1.67%
2024/07/1500.003498.9898.40-34663-5.12%
2024/07/12196.7000.0095.6016480.15%
2024/07/09597.4200.0096.3056680.75%
2024/07/081100.00199.50100.5006550.00%
2024/07/0300.00397.4096.70-3628-0.48%
2024/07/02399.7300.0097.8036230.48%
2024/05/31190.6000.0090.6017290.14%
2024/05/30191.4000.0090.3017370.14%
2024/05/2700.00191.5091.70-1776-0.13%
2024/05/24192.9000.0092.8018080.12%
2024/05/22194.3000.0094.1018470.12%
2024/05/21195.6000.0095.1018500.12%
2024/04/25392.10391.1090.6001,4490.00%
2024/04/2400.00590.7690.70-51,455-0.34%
2024/04/22588.9800.0088.0051,5120.33%
2024/04/19289.9500.0089.0021,5230.13%
2024/04/16491.6800.0091.0041,5570.26%
2024/04/15594.6000.0094.1051,5650.32%
2024/04/12197.3000.0097.1011,5790.06%
2024/03/2800.001100.0099.40-11,839-0.05%
2024/03/2700.00199.9099.70-11,828-0.05%
2024/03/26298.6000.0096.8021,8180.11%
2024/03/25198.50199.30101.0001,8160.00%
2024/03/1900.00196.7096.80-11,864-0.05%
2024/03/1500.00193.6093.20-11,863-0.05%
2024/03/110.195.70495.2095.10-3.91,904-0.20%
2024/03/08196.26495.1095.10-31,924-0.15%
2024/03/07097.9000.0099.3001,9300.00%
2024/03/0600.00198.2098.10-11,937-0.05%
2024/02/291103.501102.50103.5001,9860.00%
2024/02/271104.501106.00103.0001,9950.00%
2024/02/2600.0020104.00104.50-201,990-1.00%
2024/02/165.3105.9518104.92102.00-12.72,096-0.61%
2024/02/1513.2110.6719109.00110.50-5.82,060-0.28%
智擎明、後年新藥將有斬獲 歐洲藥證+一期臨床數據結果Anue鉅亨-2023/11/03
智擎 相關文章